Statins and fibrinogen (multiple letters) [1]

Lancet

Volumn 351, Issue 9113, 1998, Pages 1430-1432

  Nair, D R ^a   Papadakis, J A ^a   Jagroop, I A ^a   Mikhailidis, D P ^a   Winder, A F ^a   Black, D M ^a   Haverkate, F ^a   Koopman, J ^a   De Maat, M P M ^a   Darko, D A ^a   O'Shea, D ^a   Wierzbicki, A S ^a   Crook, M A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FIBRINOGEN; LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; PYRROLE DERIVATIVE;

CLINICAL TRIAL; FIBRINOGEN BLOOD LEVEL; HUMAN; LETTER; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; DRUG EFFECT; METABOLISM; NOTE;

ANTICHOLESTEREMIC AGENTS; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; LIPOPROTEIN(A); PYRROLES;

EID: 0032499382     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)26019-3     Document Type: Letter

References (5)

1. AS Wierzbicki PJ Lumb YK Semra MA Crook Effect of atorvastatin on plasma fibrinogen Lancet 351 1998 569 570
2. RG Bakker-Arkema MH Davidson RJ Goldstein Efficacy and safety of a new HMG-CoA reductace inhibitor, atorvastatin, in patients with hypertriglyceridemia JAMA 275 1996 128 133
3. J Heinrich M Sandkamp R Kokott H Schulte G Assmann Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population Clin Chem 37 1991 1950 1954
4. SG Thompson J Kienast SD Pyke F Haverkate van der Loo JC Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group N Engl J Med 332 1995 635 641
5. VM Maher BG Brown SM Marcovina LA Hilger XQ Zhao JJ Albers Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JAMA 274 1995 1771 1774